# A Phase I Evaluation of the Safety and Tolerability of Pirfenidone in Idiopathic Subglottic Stenosis

> **NCT07654517** · PHASE1 · NOT_YET_RECRUITING · sponsor: **London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's** · enrollment: 40 (estimated)

## Conditions studied

- Idiopathic Subglottic Stenosis
- Subglottic Stenosis (SGS)

## Interventions

- **DRUG:** Pirfenidone 267 MG [Esbriet]
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07654517
- **Lead sponsor:** London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-01
- **Primary completion:** 2027-12-01
- **Final completion:** 2029-12-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07654517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07654517, "A Phase I Evaluation of the Safety and Tolerability of Pirfenidone in Idiopathic Subglottic Stenosis". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07654517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*